Aarti Pharmalabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs has submitted a quarterly certificate from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, under SEBI Regulation 74(5) for the quarter ended June 30, 2025. The certificate confirms that all share certificates received for dematerialisation during the quarter were duly processed, verified, and the depositories' names were substituted as registered owners in the company's register of members within prescribed timelines. No new shares were issued or transferred — this is purely a procedural confirmation that routine demat requests from shareholders were handled correctly. The filing has been made to both BSE (Scrip Code: 543748) and NSE (Symbol: AARTIPHARM).
This is a routine regulatory compliance filing with no material impact on shareholders or stock price. It simply confirms normal administrative processing of share dematerialisation requests during the quarter.